Monte Rosa Therapeutics presents plans for four Phase 2 trial starts in 2026
GLUE•GLUE•GLUE•GLUE•Monte Rosa Therapeutics expects its cash runway to extend into 2029 and says potential collaboration payments exceed $350 million over the next 24 months. It plans Phase 2 trials of MRT-8102 for gout in Q4 2026, with studies for two other conditions planned for the first half of 2027.
Monte Rosa Therapeutics expects its cash runway to extend into 2029, covering multiple anticipated Phase 2 studies across its three clinical programs. The company says potential collaboration payments exceed $350 million over the next 24 months, following more than $400 million received over the past three years.
Novartis is conducting Phase 2a/b trials of MRT-6160 in Sjögren's disease and psoriatic arthritis, with additional Phase 2 studies expected. Monte Rosa plans Phase 2 trials of MRT-8102 for gout in Q4 2026 and for coronary artery disease and hidradenitis suppurativa in the first half of 2027. Its Phase 2 trial of MRT-2359 in AR-mutant metastatic castration-resistant prostate cancer is ongoing, with an update expected in 2027.
